关于召开 2024 年第二次临时股东大会的通知 证券代码：002172 证券简称：澳洋健康 公告编号：2024-35 江苏澳洋健康产业股份有限公司 关于召开 2024 年第二次临时股东大会通知的公告 本公司及董事会全体成员保证公告内容的真实、准确、完整，没有虚假记 载、误导性陈述或者重大遗漏。 江苏澳洋健康产业股份有限公司（以下简称"公司"）第八届董事会第二十四 次会议决定于 2024 年 11 月 25 日（星期一）下午 14:00 在张家港市杨舍镇塘市 澳洋国际大厦 A 座会议室召开公司 2024 年第二次临时股东大会，本次股东会议 采取现场投票与网络投票相结合的方式。现将本次会议有关事项通知如下： 一、会议召开的基本情况 1、股东大会届次：2024 年第二次临时股东大会。 2、会议召集人：公司董事会。公司于 2024 年 11 月 8 日召开第八届董事会 第二十四次会议审议通过了《关于召开 2024 年第二次临时股东大会的议案》，同 意召开本次股东大会。 3、会议召开的合法合规性说明：本次股东大会会议召开符合有关法律、行 政法规、部门规章、规范性文件、深圳证券交易所业务规则和公司章程等相关规 定。 4、 ...

第八届董事会第二十四次会议决议公告 证券代码：002172 证券简称：澳洋健康 公告编号：2024-33 江苏澳洋健康产业股份有限公司 一、审议通过《关于为全资子公司提供反担保的议案》 表决结果：同意 9 票，反对 0 票，弃权 0 票。 上述议案的详细内容，请见同日《证券时报》或公司指定信息披露网站（巨 第八届董事会第二十四次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚 假记载、误导性陈述或者重大遗漏负连带责任。 江苏澳洋健康产业股份有限公司（以下简称"澳洋健康"或"公司"）第八 届董事会第二十四次会议于 2024 年 10 月 29 日以通讯方式发出会议通知，于 2024 年 11 月 8 日下午在公司会议室以现场结合通讯方式召开。会议应出席董事 9 名， 实际出席会议董事 9 名。公司监事及高管列席了会议。会议由公司董事长沈学如 先生主持，符合《公司法》及公司《章程》的有关规定。会议经认真审议，通过 如下议案： 因公司全资子公司张家港澳洋医院有限公司经营发展需要，拟向中国光大银 行股份有限公司张家港支行（以下简称"光大张家港支行"）申请授信（包括但 不限于借款、开立银票 ...

关于为全资子公司提供反担保的公告 证券代码：002172 证券简称：澳洋健康 公告编号：2024-34 江苏澳洋健康产业股份有限公司 关于为全资子公司提供反担保的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚 假记载、误导性陈述或者重大遗漏负连带责任。 一、 担保情况概述 江苏澳洋健康产业股份有限公司（以下简称"公司"）于2024年11月8日召 开第八届董事会第二十四次会议，审议通过了《关于为全资子公司提供反担保的 议案》。 因公司全资子公司张家港澳洋医院有限公司（以下简称"澳洋医院"）经营 发展需要，拟向中国光大银行股份有限公司张家港支行（以下简称"光大张家港 支行"）申请授信（包括但不限于借款、开立银票、信用证、打包贷款、其他融 资业务其他非融资业务）2,000万元，期限1年。由张家港市金港投融资担保有限 公司（以下简称"金港投融"）为澳洋医院银行授信提供担保，并由公司向金港 投融提供全额反担保，期限为履行垫付之日起三年。 公司与金港投融之间不存在关联关系，本次反担保不构成关联交易。根据《深 圳证券交易所股票上市规则》及《公司章程》等相关规定，本次反担保事项尚需 提交股东大会审议。 ...

Financial Performance - The company's operating revenue for Q3 2024 was ¥469,718,772.02, a decrease of 16.12% compared to ¥559,970,261.09 in the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥1,350,111.61, down 67.84% from ¥4,202,063.52 year-on-year[2] - The basic earnings per share for Q3 2024 was ¥0.0018, a decline of 67.27% compared to ¥0.0055 in the same period last year[2] - Total operating revenue for the current period is $1,501,392,158.94, a decrease of 7.5% from $1,623,745,504.62 in the previous period[13] - Net profit for the current period is $39,622,828.72, slightly down by 0.7% from $39,898,732.72 in the previous period[13] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥229,235,524.51, a decrease of 23.89% compared to -¥185,029,234.52 in the previous year[2] - Cash inflow from operating activities increased to $1,762,781,352.49, up 7.1% from $1,646,450,086.07 in the previous period[15] - Net cash flow from financing activities decreased by 35.22% compared to the same period last year, as the decline in cash paid for financing activities exceeded the decrease in cash received[9] - Cash paid for other operating activities was 200,691,363.19 CNY, down from 246,981,929.68 CNY, a decrease of about 18.7%[16] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,932,468,426.22, down 13.78% from ¥2,241,371,837.83 at the end of the previous year[3] - Total liabilities decreased from CNY 2,166,565,617.51 to CNY 1,818,939,377.18, a reduction of around 16%[11] - Current assets decreased from CNY 1,320,065,483.65 to CNY 1,030,035,440.89, a decline of about 22%[11] Equity - The equity attributable to shareholders increased by 41.20% to ¥132,555,288.39 from ¥93,877,216.04 year-on-year[3] - The company's total equity increased from CNY 74,806,220.32 to CNY 113,529,049.04, an increase of approximately 51.7%[12] Investments - Long-term equity investments increased by 3602.41% compared to the beginning of the period, attributed to additional investments in joint ventures[8] - The company's long-term equity investments increased significantly from CNY 386,950.60 to CNY 14,326,493.92, a substantial increase of over 3700%[11] - Cash inflow from investment activities decreased by 99.90% compared to the same period last year, primarily due to a reduction in fixed asset disposals and no occurrence of subsidiary equity disposals[8] Expenses - Research and development expenses decreased by 100.00% compared to the same period last year, as no R&D expenses were incurred during the period[8] - Financial expenses decreased by 40.82% compared to the same period last year, due to increased interest income from matured time deposits used for guarantees[8] - Sales expenses decreased to $32,167,433.29, down 12.5% from $36,789,275.31 in the previous period[13] - Management expenses decreased to $92,868,985.94, down 4.0% from $97,560,377.11 in the previous period[13] Government Support - The company received government subsidies amounting to ¥593,092.25 during the reporting period, contributing positively to the financial results[6] Non-recurring Items - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 277.78% to ¥1,442,301.72 from ¥385,527.75 in the previous year[2] - Non-recurring losses totaled -¥92,190.11 for the reporting period, with a year-to-date total of ¥2,848,614.89[6]

Financial Performance - The company's operating revenue for the reporting period was CNY 1,031,673,386.92, a decrease of 3.02% compared to the previous year[12]. - The net profit attributable to shareholders was CNY 37,327,960.74, representing an increase of 5.36% year-on-year[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 34,387,155.74, up 14.90% from the previous year[12]. - The net cash flow from operating activities was negative CNY 253,412,500.73, a decline of 281.75% compared to the previous year[12]. - The total assets at the end of the reporting period were CNY 1,984,965,380.48, down 11.44% from the end of the previous year[12]. - The net assets attributable to shareholders increased to CNY 131,205,176.78, a rise of 39.76% compared to the previous year[12]. - The weighted average return on net assets was 33.17%, a decrease of 23.99% from the previous year[12]. - The company reported a 62.18% decrease in financial expenses, amounting to ¥5,929,527.72, down from ¥15,679,201.76 in the previous year[21]. - The company reported a net profit distribution of CNY -2,254,000.00 for the current period, highlighting a focus on reinvestment[96]. Revenue Segmentation - Revenue from the pharmaceutical logistics segment was CNY 523,946,772.45, accounting for 50.79% of total revenue, down 4.93% year-on-year[24]. - Revenue from the medical services segment was CNY 507,726,614.47, representing 49.21% of total revenue, with a slight decrease of 0.46% compared to the previous year[24]. - The gross profit margin for the pharmaceutical logistics segment was 7.75%, down 0.53% year-on-year, while the medical services segment had a gross profit margin of 19.40%, down 1.13%[24]. Investment and Expansion - The company is exploring investment opportunities in the healthcare industry to enhance its competitive edge[19]. - The company has established a large modern pharmaceutical distribution network covering East China, with a warehouse area of 32,000 square meters[22]. - The company has entered the health sector with the establishment of Jiangsu Aoyang Biotechnology Co., Ltd., focusing on functional foods and health products[22]. - The ongoing major non-equity investment project, Aoyang Hospital Phase IV, has a total investment of CNY 9,024,586.92, with 57.75% of the project completed[30]. - The company plans to enhance its brand and expand its business by developing key medical disciplines such as orthopedics, oncology, and urology, while also growing its aesthetic medicine and health management services[36]. Cash Flow and Liquidity - The company's cash and cash equivalents decreased by 32.64% to ¥236,378,240.52 from ¥350,919,280.95 at the beginning of the year[22]. - The company's cash and cash equivalents dropped from CNY 245,874,934.95 to CNY 76,320,129.49, a decrease of approximately 69.0%[78]. - Cash flow from operating activities showed a net outflow of CNY -253,412,500.73 in the first half of 2024, contrasting with a net inflow of CNY 139,430,871.19 in the same period of 2023[87]. - The net cash flow from investing activities was -¥10,205,088.50, an improvement from -¥18,794,757.11 in the first half of 2023[90]. Shareholder Information - The company reported a total share count of 765,732,360 shares, with 99.94% being unrestricted shares[62]. - The largest shareholder, Aoyang Group Co., Ltd., holds 235,349,599 shares, accounting for 30.74% of total shares[64]. - The second-largest shareholder, Shen Qing, holds 17,166,000 shares, representing 2.24% of total shares[67]. - The company did not distribute cash dividends or issue bonus shares for the half-year period, nor did it increase share capital from capital reserves[40]. Risk Factors - The company has acknowledged risks related to national policies affecting the healthcare industry[3]. - The company faces macroeconomic risks due to the ongoing global economic downturn, which may restrict consumer demand and purchasing power, particularly for mid-to-high-end consumption[36]. - The company is actively monitoring national healthcare policy changes and is prepared to adjust its business strategies accordingly, focusing on innovation in medical services and technology[36]. Social Responsibility and Governance - The company has engaged in various social responsibility initiatives, including free medical consultations in communities, which have received positive feedback from the public[41]. - The company has not faced any significant environmental penalties during the reporting period and has not disclosed any other environmental information[41]. - There were no non-operational fund occupations by controlling shareholders or related parties during the reporting period[42]. Accounting Policies and Changes - The company has undergone changes in accounting policies, which required restatement of previous financial data[12]. - The financial report for the first half of 2024 has not been audited[74]. - The company applies expected credit loss accounting for financial assets measured at amortized cost and those measured at fair value with changes recognized in other comprehensive income[122]. Inventory and Receivables - The company reported a total inventory balance of CNY 183,417,853.92 at the end of the period, compared to CNY 177,560,402.42 at the beginning of the period[193]. - The provision for bad debts on accounts receivable was 11.29% of the total balance, with a total provision amounting to ¥27,093,109.19, reflecting a provision coverage ratio of 69.84%[171]. - The company has a significant amount of overdue receivables, with CNY 58,551,801.31 classified as over three years old[183]. Future Outlook - The company plans to focus on market expansion and new product development in the upcoming quarters to drive future growth[82]. - The overall financial performance indicates a strategic focus on long-term growth despite short-term profit challenges[96].

江苏澳洋健康产业股份有限公司 2024 年半年度 非经营性资金占用及其他关联资金往来情况汇总表 | 南通市阳光澳洋护理院有限 | 同一最终控制方 | 应收账款 | - | 17.38 | 17.03 | 0.35 | 药品销售 | 经营性往来 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 公司 -物流 | | | | | | | | | | 南通市阳光澳洋护理院有限 公司 -数字技术 | 同一最终控制方 | 应收账款 | - | 0.65 | | 0.65 | 技术服务 | 经营性往来 | | 张家港华盈彩印包装有限公 司-母公司 | 控股股东参股企业 | 应收账款 | 2.36 | | | 2.36 | 供应电力 | 经营性往来 | | 江苏澳洋置业有限公司 -佳隆 | 同一最终控制方 | 应收账款 | - | 2.22 | 1.90 | 0.32 | 药品销售 | 经营性往来 | | 江苏澳洋置业有限公司 -数字 技术 | 同一最终控制方 | 应收账款 | - | 0.07 | 0.03 | 0.04 | 耗材 | 经营性往来 | ...

名 称 江苏证监局关于对周群信采取出具警示函措施的决定 文 号 〔2024〕129号 主 题 词 江苏证监局关于对周群信采取出具警示函措施的决定 周群信: 索 引 号 bm56000001/2024-00008972 分 类 发布机构 发文日期 1720994700000 【打印】 【关闭窗口】 你担任江苏澳洋健康产业股份有限公司(以下简称公司)独立董事期间,你女儿周晓阳于2023年3月23 日至2023年3月29日期间,买入公司股票18.66万股,累计成交金额70.17万元;2023年4月11日,卖出公司股票 18.66万股,成交金额68.86万元。 上述交易行为导致你构成《中华人民共和国证券法》第四十四条第一款、第二款规定的短线交易行 为,根据《中华人民共和国证券法》第一百七十条第二款规定,我局决定对你采取出具警示函的行政监管 措施,并记入证券期货市场诚信档案。你应充分汲取教训,加强对证券法律法规的学习,规范本人及近亲属 的证券交易行为,杜绝此类违规行为再次发生,并于收到本决定书之日起10个工作日内向我局提交书面报 告。 如对本监督管理措施不服,可以在收到本决定书之日起60日内向中国证券监督管理委员会提出 ...

江苏世纪同仁律师事务所 江苏澳洋健康产业股份有限公司 澳洋健康 2024 年第一次临时股东大会 法律意见书 2024 年第一次临时股东大会的法律意见书 致：江苏澳洋健康产业股份有限公司 根据《中华人民共和国公司法》《中华人民共和国证券法》和中国证券监督 管理委员会《上市公司股东大会规则》等法律、法规和规范性文件以及《江苏澳 洋健康产业股份有限公司章程》（以下简称"《公司章程》"）的规定，江苏世 纪同仁律师事务所（以下简称"本所"）受贵公司董事会的委托，指派本所律师 出席贵公司 2024 年第一次临时股东大会，并就本次股东大会的召集、召开程序、 出席会议人员资格、召集人资格、表决程序以及表决结果的合法有效性等事项出 具法律意见。 为出具本法律意见书，本所律师对本次股东大会所涉及的有关事项进行了审 查，查阅了相关会议文件，并对有关问题进行了必要的核查和验证。 本所律师同意将本法律意见书随贵公司本次股东大会决议一并公告，并依法 对本法律意见书承担相应的责任。 本所律师根据相关法律、法规和规范性文件的要求，按照律师行业公认的业 务标准、道德规范和勤勉尽责精神，出具法律意见如下： 一、关于本次股东大会的召集、召开程序和 ...

2024 年第一次临时股东大会会议决议公告 证券代码：002172 证券简称：澳洋健康 公告编号：2024-30 江苏澳洋健康产业股份有限公司 2024 年第一次临时股东大会会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确、完整，没有虚假记 载、误导性陈述或者重大遗漏。 一、 特别提示 1、本次股东大会召开期间没有发生增加、否决或变更议案的情况； 2、本次股东大会未涉及变更前次股东大会决议的情况； 3、本次股东大会采取现场投票、网络投票相结合的方式召开。 4、 召集人：江苏澳洋健康产业股份有限公司董事会； 5、 主持人：董事长沈学如； 6、 会议的召开符合《公司法》《股票上市规则》及《公司章程》的相关规 定。 三、 会议的出席情况 1、出席会议股东的总体情况： 通过现场和网络投票的股东 12 人，代表股份 255,187,239 股，占上市公司总 股份的 33.3259％。 二、 会议召开的情况 1、 召开时间：2024 年 6 月 24 日下午 14:00； 2、 召开地点：张家港市杨舍镇塘市澳洋国际大厦 A 座会议室； 3、 召开方式：本次股东会议采取现场投票与网络投票相结合的方式； 1、审议 ...

本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚 假记载、误导性陈述或者重大遗漏负连带责任。 江苏澳洋健康产业股份有限公司（以下简称"澳洋健康"或"公司"）第八 届董事会第二十一次会议于 2024 年 5 月 28 日以通讯方式发出会议通知，于 2024 年 6 月 7 日下午在公司会议室以现场结合通讯方式召开。会议应出席董事 9 名， 实际出席会议董事 9 名。会议由公司董事长沈学如先生主持，符合《公司法》及 公司《章程》的有关规定。公司监事及高管列席了会议。会议经认真审议，通过 如下议案： 一、审议通过《关于全资子公司增资及公司放弃优先认购权暨关联交易的 议案》 第八届董事会第二十一次会议决议公告 证券代码：002172 证券简称：澳洋健康 公告编号：2024-26 江苏澳洋健康产业股份有限公司 第八届董事会第二十一次会议决议公告 二、审议通过《关于召开 2024 年第一次临时股东大会的议案》 同意于 2024 年 6 月 24 日召开江苏澳洋健康产业股份有限公司 2024 年第一 次临时股东大会。 表决结果：同意9票，反对0票，弃权0票。 江苏澳洋健康产业股份有限公司（以下简称"澳洋健康 ...